{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:07:39Z","timestamp":1790636859817,"version":"4.1.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K23HD104517"],"award-info":[{"award-number":["K23HD104517"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI129854"],"award-info":[{"award-number":["K23AI129854"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11904-022-00641-x","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:14:41Z","timestamp":1667038481000},"page":"455-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evidence for Implementation: Management of TB in HIV and Pregnancy"],"prefix":"10.1007","volume":"19","author":[{"given":"Amanda J.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti S.","family":"Mathad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-9840","authenticated-orcid":false,"given":"Ahizechukwu C.","family":"Eke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"641_CR1","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global tuberculosis report. Geneva, Switzerland: World Health Organization; 2021."},{"issue":"5","key":"641_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf Dis. 2020;20(5):533\u20134.","journal-title":"Lancet Inf Dis"},{"key":"641_CR3","unstructured":"World Health Organization.\u00a0TB\/HIV: a clinical manual (World Health Organization, Geneva, Switzerland, 2004 2nd ed.)"},{"issue":"2","key":"641_CR4","first-page":"115","volume":"49","author":"M Connolly","year":"1996","unstructured":"Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q. 1996;49(2):115\u20139.","journal-title":"World Health Stat Q"},{"issue":"2","key":"641_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1086\/426827","volume":"191","author":"P Sonnenberg","year":"2005","unstructured":"Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191(2):150\u20138.","journal-title":"J Infect Dis"},{"issue":"3","key":"641_CR6","first-page":"1271","volume":"157","author":"D Goletti","year":"1996","unstructured":"Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation J Immunol. 1996;157(3):1271\u20138.","journal-title":"Role of immune activation J Immunol"},{"issue":"4","key":"641_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJM199201233260404","volume":"326","author":"CL Daley","year":"1992","unstructured":"Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326(4):231\u20135.","journal-title":"N Engl J Med."},{"issue":"9","key":"641_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJM198903023200901","volume":"320","author":"PA Selwyn","year":"1989","unstructured":"Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320(9):545\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"641_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00126334-200001010-00010","volume":"23","author":"R Wood","year":"2000","unstructured":"Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23(1):75\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"641_CR10","first-page":"572","volume":"110","author":"GW Comstock","year":"1974","unstructured":"Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis. 1974;110(5):572\u201380.","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"641_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/aje\/kwk116","volume":"165","author":"H L\u00f3pez-Gatell","year":"2007","unstructured":"L\u00f3pez-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007;165(10):1134\u201342.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"641_CR12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cid\/cis732","volume":"55","author":"JS Mathad","year":"2012","unstructured":"Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532\u201349.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"641_CR13","doi-asserted-by":"publisher","first-page":"e62211","DOI":"10.1371\/journal.pone.0062211","volume":"8","author":"CJ Hoffmann","year":"2013","unstructured":"Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, et al. High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS ONE. 2013;8(4):e62211.","journal-title":"PLoS ONE"},{"issue":"12","key":"641_CR14","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1016\/S2214-109X(14)70330-4","volume":"2","author":"J Sugarman","year":"2014","unstructured":"Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2(12):e710\u20136.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"641_CR15","first-page":"983","volume":"91","author":"T Pillay","year":"2001","unstructured":"Pillay T, Khan M, Moodley J, Adhikari M, Padayatchi N, et al. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban. KwaZulu-Natal S Afr Med J. 2001;91(11):983\u20137.","journal-title":"KwaZulu-Natal S Afr Med J"},{"issue":"14","key":"641_CR16","first-page":"1857","volume":"15","author":"M Khan","year":"2021","unstructured":"Khan M, Pillay T, Moodley JM, Connolly CA, Durban Perinatal TB HIV-1 Study Group. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban. South Africa AIDS. 2021;15(14):1857\u201363.","journal-title":"South Africa AIDS"},{"issue":"2","key":"641_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/518974","volume":"45","author":"A Gupta","year":"2007","unstructured":"Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Byramjee Jeejeebhoy Medical College-Johns Hopkins University Study Group, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002\u20132005. Clin Infect Dis. 2007;45(2):241\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"641_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1473-3099(04)00939-9","volume":"4","author":"T Pillay","year":"2004","unstructured":"Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis. 2004;4(3):155\u201365.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"641_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/cix851","volume":"66","author":"N Salazar-Austin","year":"2018","unstructured":"Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, et al. TSHEPISO Study Team Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: the Tshepiso study. Clin Infect Dis. 2018;66(6):921\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"641_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0020-7292(94)90064-7","volume":"44","author":"N Jana","year":"1994","unstructured":"Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet. 1994;44(2):119\u201324.","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"641_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199908263410903","volume":"341","author":"N Jana","year":"1999","unstructured":"Jana N, Vasishta K, Saha SC, Ghosh K. Obstetrical outcomes among women with extrapulmonary tuberculosis. N Engl J Med. 1999;341(9):645\u20139.","journal-title":"N Engl J Med"},{"key":"641_CR22","doi-asserted-by":"crossref","unstructured":"Eke AC. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol. 2021 Dec 8. Epub ahead of print.","DOI":"10.1515\/jbcpp-2021-0312"},{"issue":"5","key":"641_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/17425255.2013.781153","volume":"9","author":"JC Schoen","year":"2013","unstructured":"Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013;9(5):573\u201388.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"641_CR24","unstructured":"Institute of M, National Research Council Committee to Reexamine IOMPWG. The National Academies Collection: reports funded by National Institutes of Health. In: Rasmussen KM, Yaktine AL, editors. Weight gain during pregnancy: reexamining the guidelines. Washington (DC), National Academies Press (US); 2009."},{"key":"641_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0889-8553(21)00599-9","volume":"21","author":"GT Everson","year":"1992","unstructured":"Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin N Am. 1992;21:751\u201376.","journal-title":"Gastroenterol Clin N Am"},{"key":"641_CR26","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1093\/cid\/ciu709","volume":"59","author":"JS Sheffield","year":"2014","unstructured":"Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014;59:S437\u201344.","journal-title":"Clin Infect Dis"},{"key":"641_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0378-3782(87)90039-9","volume":"15","author":"MR Holdiness","year":"1987","unstructured":"Holdiness MR. Teratology of the antituberculosis drugs. Early Hum Dev. 1987;15:61\u201374.","journal-title":"Early Hum Dev"},{"issue":"2","key":"641_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","volume":"3","author":"G Acocella","year":"1978","unstructured":"Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3(2):108\u201327.","journal-title":"Clin Pharmacokinet."},{"key":"641_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0041-008X(83)90122-9","volume":"69","author":"JC Greenaway","year":"1983","unstructured":"Greenaway JC, Fantel AG. Enhancement of rifampin teratogenicity in cultured rat embryos. Toxicol Appl Pharmacol. 1983;69:81\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"key":"641_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pnpbp.2012.01.004","volume":"37","author":"KN Bharathi","year":"2012","unstructured":"Bharathi KN, Natesh TS, Ashwitha RA. Prenatal exposure to anti tubercular drugs and postnatal effect on growth, development and cognitive ability in rats. Prog Neuro-Psychopharm Biol Psych. 2012;37:203\u20139.","journal-title":"Prog Neuro-Psychopharm Biol Psych"},{"key":"641_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5694\/j.1326-5377.1966.tb19426.x","volume":"1","author":"BF Statford","year":"1966","unstructured":"Statford BF. Observations on laboratory rodents treated with \u2018rifamide\u2019 during pregnancy. Med J Aust. 1966;1:10\u20132.","journal-title":"Med J Aust"},{"key":"641_CR32","first-page":"227","volume":"54","author":"GN Rao","year":"2000","unstructured":"Rao GN, Giles HD. Reproductive and developmental toxicity of AIDS combination therapies in Swiss (CD-1) mice. Toxicologist. 2000;54:227.","journal-title":"Toxicologist"},{"key":"641_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","volume":"28","author":"E Ribera","year":"2001","unstructured":"Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28:450\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"641_CR34","doi-asserted-by":"crossref","unstructured":"Eke AC, Dooley KE, Sheffield JS. Pharmacologic research in pregnant women - time to get it right. N Engl J Med. 2019 Apr 4;380(14):1293\u20131295. Erratum in: N Engl J Med. 2019 Jul 11;381(2):194.","DOI":"10.1056\/NEJMp1815325"},{"issue":"7","key":"641_CR35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/1471-0528.15027","volume":"125","author":"KB Simmons","year":"2018","unstructured":"Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018;125(7):804\u201311.","journal-title":"BJOG"},{"key":"641_CR36","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. SIRTURO (Bedaquiline) Pharmacology\/Toxicology NDA Review and Evaluation. 2012. Application 204\u2013384."},{"issue":"3","key":"641_CR37","doi-asserted-by":"publisher","first-page":"1601724","DOI":"10.1183\/13993003.01724-2016","volume":"49","author":"E Van Kampenhout","year":"2017","unstructured":"Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, et al. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601724.","journal-title":"Eur Respir J"},{"key":"641_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1183\/09031936.00176610","volume":"38","author":"AD Pranger","year":"2011","unstructured":"Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 2011;38:888\u201394.","journal-title":"Eur Respir J"},{"key":"641_CR39","unstructured":"Centers for Disease Control and Prevention. Treatment of multidrug-resistant tuberculosis: bedaquiline. Accessed on January 4, 2022"},{"key":"641_CR40","doi-asserted-by":"publisher","unstructured":"Jaspard M, Elefant-Amoura E, Melonio I, De Montgolfier I, Veziris N, Caumes E. Bedaquiline and linezolid for extensively drug-resistant tuberculosis in pregnant woman. Emerg Infect Dis. 2017;23:\u00a0https:\/\/doi.org\/10.3201\/eid2310.161398","DOI":"10.3201\/eid2310.161398"},{"key":"641_CR41","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1183\/09031936.00001913","volume":"42","author":"MS Bolhuis","year":"2013","unstructured":"Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013;42:1614\u201321.","journal-title":"Eur Respir J"},{"issue":"2","key":"641_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0301-2115(95)02524-3","volume":"69","author":"C Schaefer","year":"1996","unstructured":"Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol. 1996;69(2):83\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"641_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAI.0b013e3182410503","volume":"59","author":"KE Dooley","year":"2012","unstructured":"Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, et al. ACTG 5267 Study Team Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012;59(5):455\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"641_CR44","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1128\/AAC.03246-14","volume":"58","author":"EM Svensson","year":"2014","unstructured":"Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"641_CR45","first-page":"736","volume-title":"Red book: report of the Committee on infectious diseases","author":"American Academy of Pediatrics","year":"2012","unstructured":"American Academy of Pediatrics. Tuberculosis. In: Pickering LK, editor. Red book: report of the Committee on infectious diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012. p. 736\u201356.","edition":"29"},{"issue":"3","key":"641_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archinte.1984.00350150199040","volume":"144","author":"DE Snider Jr","year":"1984","unstructured":"Snider DE Jr, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med. 1984;144(3):589\u201390.","journal-title":"Arch Intern Med"},{"issue":"3","key":"641_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-117-3-177","volume":"117","author":"MA Fischl","year":"1992","unstructured":"Fischl MA, Uttamchandani RB, Daikos GL, Poblete RB, Moreno JN, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992;117(3):177\u201383.","journal-title":"Ann Intern Med"},{"issue":"23","key":"641_CR48","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJM199206043262302","volume":"326","author":"BR Edlin","year":"1992","unstructured":"Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326(23):1514\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"641_CR49","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/jac\/dkz557","volume":"75","author":"D Atwine","year":"2020","unstructured":"Atwine D, Baudin E, Gel\u00e9 T, Muyindike W, Mworozi K, ANRS 12292 Rifavirenz study group, et al. Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. J Antimicrob Chemother. 2020;75(5):1250\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"641_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","volume":"42","author":"G Ramachandran","year":"2006","unstructured":"Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr. 2006;42:36\u201341.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"641_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1086\/510078","volume":"44","author":"W Manosuthi","year":"2007","unstructured":"Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44:141\u20134.","journal-title":"Clin Infect Dis"},{"key":"641_CR52","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/135965350501000809","volume":"10","author":"RS Autar","year":"2005","unstructured":"Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10:937\u201343.","journal-title":"Antivir Ther"},{"issue":"11","key":"641_CR53","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","volume":"219","author":"RKR Rajoli","year":"2019","unstructured":"Rajoli RKR, Curley P, Chiong J, Back D, Flexner C, et al. Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis. 2019;219(11):1735\u201342.","journal-title":"J Infect Dis"},{"key":"641_CR54","doi-asserted-by":"crossref","unstructured":"Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996 Apr;22 Suppl 1:S15\u201321; discussion S21\u20132.","DOI":"10.1093\/clinids\/22.Supplement_1.S15"},{"issue":"10","key":"641_CR55","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1128\/AAC.01749-09","volume":"54","author":"V Sekar","year":"2010","unstructured":"Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54(10):4440\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"641_CR56","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","volume":"48","author":"CJ la Porte","year":"2004","unstructured":"la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(5):1553\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"641_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 3","key":"641_CR58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2047-783X-14-S3-17","volume":"14","author":"DM Burger","year":"2009","unstructured":"Burger DM. Drug-drug interactions with raltegravir. Eur J Med Res. 2009;14(Suppl 3):17\u201321.","journal-title":"Eur J Med Res"},{"issue":"9","key":"641_CR59","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"H Masur","year":"2014","unstructured":"Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308\u201311.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"641_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1155\/S1064744998000040","volume":"6","author":"NL Eriksen","year":"1998","unstructured":"Eriksen NL, Helfgott AW. Cutaneous anergy in pregnant and nonpregnant women with human immunodeficiency virus. Infect Dis Obstet Gynecol. 1998;6(1):13\u20137.","journal-title":"Infect Dis Obstet Gynecol"},{"key":"641_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1513\/pats.200511-119JH","volume":"3","author":"P Nahid","year":"2006","unstructured":"Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006;3:103\u201310.","journal-title":"Proc Am Thorac Soc"},{"key":"641_CR62","unstructured":"World Health Organization. Latent TB infection: updated and consolidated guidelines for programmatic management. 2018. Accessed on January 14, 2021."},{"key":"641_CR63","unstructured":"Centers for Disease Control and Prevention. Treatment for TB disease & pregnancy. Accessed on January 17, 2022."},{"issue":"14","key":"641_CR64","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","volume":"381","author":"A Gupta","year":"2019","unstructured":"Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, et al. IMPAACT P1078 TB APPRISE Study Team Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333\u201346. This article provides landmark data regarding deferral of latent TB treatment until after delivery in pregnant women living with HIV.","journal-title":"N Engl J Med"},{"issue":"12","key":"641_CR65","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMc1916664","volume":"382","author":"T Tiendrebeogo","year":"2020","unstructured":"Tiendrebeogo T, Anglaret X, Becquet R. HIV, Pregnancy, and Isoniazid Preventive Therapy. N Engl J Med. 2020;382(12):1184.","journal-title":"N Engl J Med"},{"key":"641_CR66","unstructured":"United States Department of Health and Human Services, Clinicalinfo.hiv.gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Accessed on January 28, 2021."},{"issue":"5","key":"641_CR67","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","volume":"15","author":"RN Moro","year":"2018","unstructured":"Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, et al. Exposure to latent tuberculosis treatment during pregnancy The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018;15(5):570\u201380.","journal-title":"Ann Am Thorac Soc."},{"issue":"6","key":"641_CR68","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/cid\/ciz1024","volume":"71","author":"N Salazar-Austin","year":"2020","unstructured":"Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ, et al. Isoniazid preventive therapy and pregnancy outcomes in women living with human immunodeficiency virus in the Tshepiso cohort. Clin Infect Dis. 2020;71(6):1419\u201326.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"641_CR69","first-page":"523","volume":"10","author":"JH Day","year":"2006","unstructured":"Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis. 2006;10(5):523\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"641_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijid.2021.09.010","volume":"112","author":"R Bhosale","year":"2021","unstructured":"Bhosale R, Alexander M, Deshpande P, Kulkarni V, Gupte N, Gupta A, Mathad J. Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: findings from PRACHITi, a cohort study in Pune. India Int J Infect Dis. 2021;112:205\u201311.","journal-title":"India Int J Infect Dis"},{"issue":"11","key":"641_CR71","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/cid\/cis732","volume":"55","author":"JS Mathad","year":"2012","unstructured":"Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532\u201349.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"641_CR72","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1473-3099(10)70078-5","volume":"10","author":"SD Lawn","year":"2010","unstructured":"Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10(7):489\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"641_CR73","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1164\/rccm.201004-0598OC","volume":"182","author":"K Middelkoop","year":"2010","unstructured":"Middelkoop K, Bekker LG, Myer L, Whitelaw A, Grant A, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182(8):1080\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"641_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0895-4356(01)00455-3","volume":"55","author":"NH Long","year":"2002","unstructured":"Long NH, Diwan VK, Winkvist A. Difference in symptoms suggesting pulmonary tuberculosis among men and women. J Clin Epidemiol. 2002;55(2):115\u201320.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"641_CR75","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/QAI.0b013e31821ac9c1","volume":"57","author":"CR Gounder","year":"2011","unstructured":"Gounder CR, Wada NI, Kensler C, Violari A, McIntyre J, Chaisson RE, Martinson NA. Active tuberculosis case-finding among pregnant women presenting to antenatal clinics in Soweto, South Africa. J Acquir Immune Defic Syndr. 2011;57(4):e77-84.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"641_CR76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2334-10-52","volume":"7","author":"FG Sheriff","year":"2010","unstructured":"Sheriff FG, Manji KP, Manji MP, Chagani MM, Mpembeni RM, Jusabani AM, Alwani ZR, Karimjee TS. Latent tuberculosis among pregnant mothers in a resource poor setting in Northern Tanzania: a cross-sectional study. BMC Infect Dis. 2010;7(10):52.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"641_CR77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejogrb.2005.07.025","volume":"126","author":"A Kothari","year":"2006","unstructured":"Kothari A, Mahadevan N, Girling J. Tuberculosis and pregnancy\u2013results of a study in a high prevalence area in London. Eur J Obstet Gynecol Reprod Biol. 2006;126(1):48\u201355.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"641_CR78","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1471-0528.2008.02097.x","volume":"116","author":"M Knight","year":"2009","unstructured":"Knight M, Kurinczuk JJ, Nelson-Piercy C, Spark P, Brocklehurst P. UKOSS Tuberculosis in pregnancy in the UK. BJOG. 2009;116(4):584\u20138.","journal-title":"BJOG"},{"issue":"7","key":"641_CR79","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u201395.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"641_CR80","first-page":"151","volume":"104","author":"AL Franks","year":"1989","unstructured":"Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104(2):151\u20135.","journal-title":"Public Health Rep"},{"issue":"3","key":"641_CR81","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5588\/ijtld.21.0753","volume":"26","author":"GB Migliori","year":"2022","unstructured":"Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis. 2022;26(3):190\u2013205.","journal-title":"Int J Tuberc Lung Dis"},{"key":"641_CR82","volume-title":"Treatment of tuberculosis: guidelines for national programmes","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: Switzerland; 2003."},{"key":"641_CR83","unstructured":"Enarson D, Rieder H, Arnodottir T, Trebucq A. Management of tuberculosis: a guide for low income countries, 4th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 1996."},{"key":"641_CR84","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR. 2003;52(RR-11).","DOI":"10.1097\/01.idc.0000086415.30743.15"},{"issue":"12","key":"641_CR85","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","volume":"12","author":"JF Murray","year":"2015","unstructured":"Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis A historical perspective. Ann Am Thorac Soc. 2015;12(12):1749\u201359.","journal-title":"Ann Am Thorac Soc."},{"issue":"6","key":"641_CR86","first-page":"452","volume":"59","author":"E Augustynowicz-Kope\u0107","year":"2002","unstructured":"Augustynowicz-Kope\u0107 E, Zwolska Z. Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers. Acta Pol Pharm. 2002;59(6):452\u20137.","journal-title":"Acta Pol Pharm."},{"issue":"3","key":"641_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00008571-199406000-00003","volume":"4","author":"HJ Lin","year":"1994","unstructured":"Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994;4(3):125\u201334.","journal-title":"Pharmacogenetics"},{"issue":"3","key":"641_CR88","first-page":"141","volume":"140","author":"YM Bromberg","year":"1955","unstructured":"Bromberg YM, Salzberger M, Bruderman I. Placental transmission of isonicotinic acid hydrazide. Gynaecologia. 1955;140(3):141\u20134.","journal-title":"Gynaecologia"},{"key":"641_CR89","first-page":"426","volume":"38","author":"CM Berlin Jr","year":"1979","unstructured":"Berlin CM Jr, Lee C. Isoniazid and acetylisoniazid disposition in human milk, saliva and plasma. Fed Proc. 1979;38:426.","journal-title":"Fed Proc"},{"issue":"4","key":"641_CR90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/00325481.1974.11713872","volume":"56","author":"H Vorherr","year":"1974","unstructured":"Vorherr H. Drug excretion in breast milk. Postgrad Med. 1974;56(4):97\u2013104.","journal-title":"Postgrad Med"},{"issue":"4","key":"641_CR91","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cpt.2044","volume":"109","author":"K Gausi","year":"2021","unstructured":"Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, IMPAACT P1078 (TB APPRISE) Study Group Team, et al. Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping. Clin Pharmacol Ther. 2021;109(4):1034\u201344.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"641_CR92","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/infdis\/jit466","volume":"209","author":"J Bertrand","year":"2014","unstructured":"Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, CAMELIA (ANRS 1295-CIPRA KH001) Study Group, et al. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis. 2014;209(3):399\u2013408.","journal-title":"J Infect Dis"},{"issue":"3","key":"641_CR93","doi-asserted-by":"publisher","first-page":"e01978","DOI":"10.1128\/AAC.01978-19","volume":"64","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Leisegang R, Dooley KE, Mathad JS, Wiesner L, McIlleron H, et al. Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV. Antimicrob Agents Chemother. 2020;64(3):e01978-e2019. Population pharmacokinetic models which describe drug dispositions of isoniazid, pyrazinamide, and ethambutol in pregnant women with tuberculosis and HIV.","journal-title":"Antimicrob Agents Chemother"},{"key":"641_CR94","first-page":"65","volume":"122","author":"DE Snider Jr","year":"1980","unstructured":"Snider DE Jr, Layde PM, Johnson MW, et al. Treatment of tuberculosis in pregnancy. Am Rev Respir Dis. 1980;122:65\u201379.","journal-title":"Am Rev Respir Dis"},{"key":"641_CR95","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0083-6729(08)60361-1","volume":"22","author":"M Wachstein","year":"1964","unstructured":"Wachstein M. Evidence for a relative B6 deficiency in pregnancy and some disease states. Vitam Horm. 1964;22:705\u201319.","journal-title":"Vitam Horm"},{"key":"641_CR96","unstructured":"Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with HIV (2001). Accessed on January 17, 2022."},{"key":"641_CR97","unstructured":"Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers. Accessed on January 13, 2022."},{"issue":"3","key":"641_CR98","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1128\/AAC.02051-15","volume":"60","author":"P Denti","year":"2015","unstructured":"Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto. South Africa Antimicrob Agents Chemother. 2015;60(3):1234\u201341.","journal-title":"South Africa Antimicrob Agents Chemother"},{"issue":"8027","key":"641_CR99","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0140-6736(77)90056-3","volume":"2","author":"I Rocker","year":"1977","unstructured":"Rocker I. Rifampicin in early pregnancy. Lancet. 1977;2(8027):48.","journal-title":"Lancet"},{"issue":"9","key":"641_CR100","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/jps.2600650921","volume":"65","author":"LI Harrison","year":"1976","unstructured":"Harrison LI, Gibaldi M. Influence of cholestasis on drug elimination: pharmacokinetics. J Pharm Sci. 1976;65(9):1346\u20138.","journal-title":"J Pharm Sci"},{"issue":"6","key":"641_CR101","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1128\/AAC.02307-13","volume":"58","author":"K Jeremiah","year":"2014","unstructured":"Jeremiah K, Denti P, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother. 2014;58(6):3468\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"641_CR102","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","volume":"50","author":"H McIlleron","year":"2006","unstructured":"McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"641_CR103","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2146\/ajhp080206","volume":"66","author":"R Yost","year":"2009","unstructured":"Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm. 2009;66(8):715\u201326.","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"641_CR104","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.5588\/ijtld.11.0068","volume":"15","author":"DJ Horne","year":"2011","unstructured":"Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15(11):1485\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"641_CR105","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1067\/mcp.2003.3","volume":"73","author":"FM Hamzeh","year":"2003","unstructured":"Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, AIDS Clinical Trials Group 365 Study Team, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther. 2003;73(3):159\u201369.","journal-title":"Clin Pharmacol Ther"},{"key":"641_CR106","unstructured":"Benedek IH, Fiske WD, White SJ, Stevenson J, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz (EFV) and rifabutin in healthy volunteers [abstract 461]. In: Program and abstracts of the Infectious Diseases Society. Denver, 1998."},{"key":"641_CR107","unstructured":"Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, et al; IMPAACT 2001 Study Team. Pharmacokinetics and safety of three months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clin Infect Dis. 2021 Jul 29:ciab665."},{"key":"641_CR108","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/thx.41.10.737","volume":"41","author":"KM Citron","year":"1986","unstructured":"Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax. 1986;41:737\u20139.","journal-title":"Thorax"},{"issue":"4","key":"641_CR109","first-page":"438","volume":"3","author":"SB Kokkada","year":"2005","unstructured":"Kokkada SB, Barthakur RB, Natarajan MN, et al. Ocular side effects of antitubercular drugs \u2013 a focus on prevention, early detection and management. Kathmandu Univ Med J (KUMJ). 2005;3(4):438\u201341.","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"issue":"3","key":"641_CR110","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0041-3879(79)90018-7","volume":"60","author":"JM Shneerson","year":"1979","unstructured":"Shneerson JM, Francis RS. Ethambutol in pregnancy\u2013foetal exposure. Tubercle. 1979;60(3):167\u20139.","journal-title":"Tubercle"},{"issue":"2","key":"641_CR111","doi-asserted-by":"publisher","first-page":"e00070","DOI":"10.1128\/MMBR.00070-19","volume":"84","author":"EA Lamont","year":"2020","unstructured":"Lamont EA, Dillon NA, Baughn AD. The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev. 2020;84(2):e00070-e119.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"641_CR112","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00404-008-0594-7","volume":"278","author":"N Keskin","year":"2008","unstructured":"Keskin N, Yilmaz S. Pregnancy and tuberculosis: to assess tuberculosis cases in pregnancy in a developing region retrospectively and two case reports. Arch Gynecol Obstet. 2008;278(5):451\u20135.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"641_CR113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","volume":"3","author":"V Ramappa","year":"2013","unstructured":"Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculous drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3(1):37\u201349.","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"641_CR114","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1067\/mcp.2002.126175","volume":"72","author":"K Ohkawa","year":"2002","unstructured":"Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculous chemotherapy-induced hepatotoxity in Japanese pediatric patients. Clin Pharmacol Ther. 2002;72(2):220\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"641_CR115","unstructured":"Centers for Disease Control and Prevention. Tuberculosis and pregnancy. Accessed on January 26, 2022."},{"key":"641_CR116","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12884-016-1096-4","volume":"16","author":"GH Bothamley","year":"2016","unstructured":"Bothamley GH, Ehlers C, Salonka I, Skrahina A, Orcau A, Codecasa LR, et al. Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey. BMC Pregnancy Childbirth. 2016;16:304.","journal-title":"BMC Pregnancy Childbirth"},{"key":"641_CR117","first-page":"637","volume":"17","author":"VK Dhingra","year":"2007","unstructured":"Dhingra VK, Mittal A, Rajpal S, Arora VK. Multidrug-resistant tuberculosis in pregnancy. J Coll Physicians Surg Pak. 2007;17:637\u20139.","journal-title":"J Coll Physicians Surg Pak"},{"key":"641_CR118","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1590\/S0037-86822011000500020","volume":"44","author":"HB Oliveira","year":"2011","unstructured":"Oliveira HB, Mateus SH. Characterization of multidrug-resistant tuberculosis during pregnancy in Campinas, State of S\u00e3o Paulo, Brazil, from 1995 to 2007 [in Portuguese]. Rev Soc Bras Med Trop. 2011;44:627\u201330.","journal-title":"Rev Soc Bras Med Trop"},{"key":"641_CR119","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1086\/374225","volume":"36","author":"S Shin","year":"2003","unstructured":"Shin S, Guerra D, Rich M, Seung KJ, Mukherjee J, Joseph K, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis. 2003;36:996\u20131003.","journal-title":"Clin Infect Dis"},{"key":"641_CR120","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s15010-007-6318-2","volume":"35","author":"P Tabarsi","year":"2007","unstructured":"Tabarsi P, Baghaei P, Mirsaeidi M, Amiri M, Mansouri D, Novin A, et al. Multi-drug resistant tuberculosis in pregnancy: need for more intensive treatment. Infection. 2007;35:477\u20138.","journal-title":"Infection"},{"key":"641_CR121","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5588\/ijtld.10.0140","volume":"15","author":"P Tabarsi","year":"2011","unstructured":"Tabarsi P, Moradi A, Baghaei P, Marjani M, Shamaei M, Mansouri N, et al. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy. Int J Tuberc Lung Dis. 2011;15:547\u201350.","journal-title":"Int J Tuberc Lung Dis"},{"key":"641_CR122","first-page":"413","volume":"81","author":"T Takashima","year":"2006","unstructured":"Takashima T, Danno K, Tamura Y, Nagai T, Matsumoto T, Han Y, et al. Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy [in Japanese]. Kekkaku. 2006;81:413\u20138.","journal-title":"Kekkaku"},{"key":"641_CR123","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1378\/chest.123.3.953","volume":"123","author":"KD Lessnau","year":"2003","unstructured":"Lessnau KD, Qarah S. Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. Chest. 2003;123:953\u20136.","journal-title":"Chest"},{"key":"641_CR124","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/514795","volume":"28","author":"AT Nitta","year":"1999","unstructured":"Nitta AT, Milligan D. Management of four pregnant women with multidrug-resistant tuberculosis. Clin Infect Dis. 1999;28:1298\u2013304.","journal-title":"Clin Infect Dis"},{"key":"641_CR125","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5505\/respircase.2015.32932","volume":"4","author":"M \u00dcnl\u00fc","year":"2015","unstructured":"\u00dcnl\u00fc M, \u00c7imen P, Ar\u0131 G, \u015eevket DM. A successfully treated severe case of extensively drug-resistant tuberculosis during pregnancy. Respir Case Rep. 2015;4:67\u201371.","journal-title":"Respir Case Rep"},{"key":"641_CR126","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/01.idc.0000078749.71576.0d","volume":"11","author":"JS Mukherjee","year":"2002","unstructured":"Mukherjee JS, Shin S, Furin J, Rich ML, L\u00e9andre F, Joseph JK, et al. New challenges in the clinical management of drug-resistant tuberculosis. Infect Dis Clin Pract. 2002;11:329\u201339.","journal-title":"Infect Dis Clin Pract"},{"key":"641_CR127","first-page":"1536281","volume":"2016","author":"M Rohilla","year":"2016","unstructured":"Rohilla M, Joshi B, Jain V, Kalra J, Prasad GR. Multidrug-resistant tuberculosis during pregnancy: two case reports and review of the literature. Case Rep Obstet Gynecol. 2016;2016:1536281.","journal-title":"Case Rep Obstet Gynecol"},{"key":"641_CR128","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2020."},{"issue":"10","key":"641_CR129","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/jama.1992.03490100078031","volume":"268","author":"C Beck-Sagu\u00e9","year":"1993","unstructured":"Beck-Sagu\u00e9 C, Dooley SW, Hutton MD, Otten J, Breeden A, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections Factors in transmission to staff and HIV-infected patients. JAMA. 1993;268(10):1280\u20136.","journal-title":"JAMA."},{"issue":"7","key":"641_CR130","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/cid\/ciaa189","volume":"72","author":"M Loveday","year":"2021","unstructured":"Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, et al. Maternal and infant outcomes among pregnant women treated for multidrug\/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2021;72(7):1158\u201368.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"641_CR131","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC.00191-13","volume":"57","author":"EM Svensson","year":"2013","unstructured":"Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"641_CR132","unstructured":"European Medicines Agency. Deltyba, INN-Delamanid \u2013 Annex I, summary of product characteristics. Accessed on January 26, 2022"},{"key":"641_CR133","unstructured":"\u201cProduct Information. Pretomanid (pretomanid).\u201d The Global Alliance for TB Drug Development, New York, NY"},{"issue":"6","key":"641_CR134","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1128\/AAC.42.6.1336","volume":"42","author":"R Loebstein","year":"1998","unstructured":"Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42(6):1336\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"641_CR135","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","volume":"107","author":"GG Nahum","year":"2006","unstructured":"Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107(5):1120\u201338.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"641_CR136","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5588\/ijtld.15.0123","volume":"19","author":"P Isaakidis","year":"2015","unstructured":"Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969\u201378.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"641_CR137","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1258\/om.2009.090002","volume":"2","author":"AM Freyer","year":"2009","unstructured":"Freyer AM. Drugs in pregnancy and lactation 8th edition: a reference guide to fetal and neonatal risk. Obstetric Medicine. 2009;2(2):89\u201389.","journal-title":"Obstetric Medicine"},{"key":"641_CR138","first-page":"178","volume":"71","author":"N Sanguigno","year":"1970","unstructured":"Sanguigno N. Considerations on ten years\u2019 use of Cycloserine. Scand J Respir Dis Suppl. 1970;71:178\u20139.","journal-title":"Scand J Respir Dis Suppl"},{"issue":"1","key":"641_CR139","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s12879-020-05416-6","volume":"18","author":"BJ van de Water","year":"2020","unstructured":"van de Water BJ, Brooks MB, Chuan-Chin Huang, et al. Tuberculosis clinical presentation and treatment outcomes in pregnancy a prospective cohort study. BMC Infect Dis. 2020;18(1):686.","journal-title":"BMC Infect Dis"},{"issue":"70 Suppl 1","key":"641_CR140","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/cid\/ciz1231","volume":"70","author":"PA Yu","year":"2020","unstructured":"Yu PA, Tran EL, Parker CM, Kim HJ, Yee EL, Smith PW, et al. Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of plague. Clin Infect Dis. 2020;70(70 Suppl 1):S37\u201350.","journal-title":"Clin Infect Dis"},{"key":"641_CR141","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","volume":"64","author":"C Vinnard","year":"2017","unstructured":"Vinnard C, King L, Munsiff S, Crossa A, Iwata K, et al. Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin Infect Dis. 2017;64:401\u20137.","journal-title":"Clin Infect Dis"},{"key":"641_CR142","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0905848","volume":"362","author":"SS Abdool Karim","year":"2010","unstructured":"Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697\u2013706.","journal-title":"N Engl J Med"},{"key":"641_CR143","doi-asserted-by":"publisher","first-page":"e46943","DOI":"10.1371\/journal.pone.0046943","volume":"7","author":"H Satti","year":"2012","unstructured":"Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS ONE. 2012;7:e46943.","journal-title":"PLoS ONE"},{"key":"641_CR144","unstructured":"Stenger EG, Aeppli L, Peheim E, Thomann PE. A contribution to the toxicology of the leprostatic drug, 3-p-(chloroanilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazine (G 30320). Acute and subchronic toxicity, reproduction toxicology. Arzneimittelforschung. 1970 Jun;20(6):794\u20139. German."},{"issue":"1","key":"641_CR145","first-page":"122","volume":"59","author":"H Farb","year":"1982","unstructured":"Farb H, West DP, Pedvis-Leftick A. Clofazimine in pregnancy complicated by leprosy. Obstet Gynecol. 1982;59(1):122\u20133.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"641_CR146","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1086\/510080","volume":"44","author":"L Elzi","year":"2007","unstructured":"Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, et al. Swiss HIV Cohort Study Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44(1):94\u2013102.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"641_CR147","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/QAD.0b013e328327964f","volume":"23","author":"JE Golub","year":"2009","unstructured":"Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631\u20136.","journal-title":"AIDS"},{"issue":"9777","key":"641_CR148","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398.","journal-title":"Lancet"},{"issue":"1","key":"641_CR149","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"key":"641_CR150","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/jama.1976.03270130044027","volume":"236","author":"JL Skolnick","year":"1976","unstructured":"Skolnick JL, Stoler BS, Katz DB. Rifampin, oral contraceptives and pregnancy. JAMA. 1976;236:1382.","journal-title":"JAMA"},{"issue":"11","key":"641_CR151","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/009127009803801109","volume":"38","author":"M LeBel","year":"1998","unstructured":"LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol. 1998;38(11):1042\u201350.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"641_CR152","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199307223290429","volume":"329","author":"RB Merkatz","year":"1993","unstructured":"Merkatz RB, Temple R, Subel S, Feiden K, Kessler DA. Women in clinical trials of new drugs A change in Food and Drug Administration policy The Working Group on Women in Clinical Trials. N Engl J Med. 1993;329(4):292\u20136.","journal-title":"N Engl J Med"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-022-00641-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:44:48Z","timestamp":1744206288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-022-00641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":152,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s11904-022-00641-x","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"12 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}